Download PDF
Semin Reprod Med 2007; 25(5): 388-401
DOI: 10.1055/s-2007-984745
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Pituitary Tumors: Diagnosis, Management, and Implications for Reproduction

Victor E. Beshay1 , Joseph E. Beshay2 , Lisa M. Halvorson1
  • 1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
  • 2Department of Neurological Surgery, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Further Information

Publication History

Publication Date:
20 August 2007 (online)

    Permissions and Reprints

ABSTRACT

Pituitary tumors are the most common intracranial neoplasms. They are commonly encountered by the gynecologist during an evaluation for galactorrhea, menstrual disturbances, or infertility. Although the majority of these tumors are benign, their impact on the endocrine and nervous system can be striking. The availability of neuroimaging techniques has allowed for more rapid diagnosis, affording earlier treatment. This review is intended to describe the common pituitary tumors seen by the gynecologist, and their impact on reproduction and fertility in the female patient.

KEYWORDS

Pituitary - adenoma - reproduction - prolactinoma

REFERENCES

  • 1 Burrow G N, Wortzman G, Rewcastle N B et al.. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series.  N Engl J Med. 1981;  304(3) 156-158
    CrossrefPubMedGoogle Scholar
  • 2 Molitch M E, Russell E J. The pituitary “incidentaloma”.  Ann Intern Med. 1990;  112(12) 925-931
    PubMedGoogle Scholar
  • 3 Hall W A, Luciano M G, Doppman J L et al.. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.  Ann Intern Med. 1994;  120(10) 817-820
    CrossrefPubMedGoogle Scholar
  • 4 Ezzat S, Asa S L. Mechanisms of disease: the pathogenesis of pituitary tumors.  Nat Clin Pract Endocrinol Metab. 2006;  2(4) 220-230
    CrossrefPubMedGoogle Scholar
  • 5 Kaltsas G A, Nomikos P, Kontogeorgos G et al.. Clinical review: diagnosis and management of pituitary carcinomas.  J Clin Endocrinol Metab. 2005;  90(5) 3089-3099
    CrossrefPubMedGoogle Scholar
  • 6 Pernicone P J, Scheithauer B W, Sebo T J et al.. Pituitary carcinoma: a clinicopathologic study of 15 cases.  Cancer. 1997;  79(4) 804-812
    CrossrefPubMedGoogle Scholar
  • 7 Ezzat S, Asa S L, Couldwell W T et al.. The prevalence of pituitary adenomas: a systematic review.  Cancer. 2004;  101(3) 613-619
    CrossrefPubMedGoogle Scholar
  • 8 Ruscalleda J. Imaging of parasellar lesions.  Eur Radiol. 2005;  15(3) 549-559
    CrossrefPubMedGoogle Scholar
  • 9 Bonneville J F, Bonneville F, Cattin F. Magnetic resonance imaging of pituitary adenomas.  Eur Radiol. 2005;  15(3) 543-548
    CrossrefPubMedGoogle Scholar
  • 10 Seilicovich A, Pisera D, Sciascia S A et al.. Gene therapy for pituitary tumors.  Curr Gene Ther. 2005;  5(6) 559-572
    CrossrefPubMedGoogle Scholar
  • 11 Modest G A, Fangman J J. Nipple piercing and hyperprolactinemia.  N Engl J Med. 2002;  347(20) 1626-1627
    CrossrefPubMedGoogle Scholar
  • 12 Pollock A, McLaren E H. Serum prolactin concentration in patients taking neuroleptic drugs.  Clin Endocrinol (Oxf). 1998;  49(4) 513-516
    CrossrefPubMedGoogle Scholar
  • 13 Slater S L, Lipper S, Shiling D J et al.. Elevation of plasma-prolactin by monoamine-oxidase inhibitors.  Lancet. 1977;  2(8032) 275-276
    PubMedGoogle Scholar
  • 14 Wiegand M, Berger M. Action of trimipramine on sleep and pituitary hormone secretion.  Drugs. 1989;  38(suppl) 135-142
    PubMedGoogle Scholar
  • 15 Peterson M C. Reversible galactorrhea and prolactin elevation related to fluoxetine use.  Mayo Clin Proc. 2001;  76(2) 215-216
    PubMedGoogle Scholar
  • 16 Steiner J, Cassar J, Mashiter K et al.. Effects of methyldopa on prolactin and growth hormone.  BMJ. 1976;  1(6019) 1186-1188
    PubMedGoogle Scholar
  • 17 Fearrington E L, Rand Jr C H, Rose J D. Hyperprolactinemia-galactorrhea induced by verapamil.  Am J Cardiol. 1983;  51(8) 1466-1467
    CrossrefPubMedGoogle Scholar
  • 18 Hou S H, Grossman S, Molitch M E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis.  Am J Kidney Dis. 1985;  6(4) 245-249
    PubMedGoogle Scholar
  • 19 Stryker T D, Molitch M E. Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency.  Am J Med. 1985;  79(2) 271-276
    CrossrefPubMedGoogle Scholar
  • 20 Van Gaal L, Abs R, De Leeuw I et al.. Hypothyroidism and prolactin.  Eur J Obstet Gynecol Reprod Biol. 1981;  12(5) 315-321
    CrossrefPubMedGoogle Scholar
  • 21 Haisenleder D J, Ortolano G A, Dalkin A C et al.. Differential actions of thyrotropin (TSH)-releasing hormone pulses in the expression of prolactin and TSH subunit messenger ribonucleic acid in rat pituitary cells in vitro.  Endocrinology. 1992;  130(5) 2917-2923
    CrossrefPubMedGoogle Scholar
  • 22 Fahie-Wilson M N, John R, Ellis A R. Macroprolactin: high molecular mass forms of circulating prolactin.  Ann Clin Biochem. 2005;  42(pt 3) 175-192
    CrossrefPubMedGoogle Scholar
  • 23 Davis J R. Prolactin and reproductive medicine.  Curr Opin Obstet Gynecol. 2004;  16(4) 331-337
    PubMedGoogle Scholar
  • 24 McNeilly A S. Prolactin and the control of gonadotrophin secretion.  J Endocrinol. 1987;  115(1) 1-5
    PubMedGoogle Scholar
  • 25 Glasow A, Breidert M, Haidan A et al.. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland.  J Clin Endocrinol Metab. 1996;  81(8) 3103-3111
    CrossrefPubMedGoogle Scholar
  • 26 Vermeulen A, Ando S. Prolactin and adrenal androgen secretion.  Clin Endocrinol (Oxf). 1978;  8(4) 295-303
    PubMedGoogle Scholar
  • 27 Lobo R A, Kletzky O A. Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia.  J Clin Endocrinol Metab. 1983;  56(3) 562-566
    PubMedGoogle Scholar
  • 28 Frieze T W, Mong D P, Koops M K. “Hook effect” in prolactinomas: case report and review of literature.  Endocr Pract. 2002;  8(4) 296-303
    PubMedGoogle Scholar
  • 29 St Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.  Clin Endocrinol (Oxf). 1996;  44(3) 305-309
    CrossrefPubMedGoogle Scholar
  • 30 Molitch M E. Disorders of prolactin secretion.  Endocrinol Metab Clin North Am. 2001;  30(3) 585-610
    CrossrefPubMedGoogle Scholar
  • 31 Colao A, Di Sarno A, Landi M L et al.. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.  J Clin Endocrinol Metab. 2000;  85(6) 2247-2252
    CrossrefPubMedGoogle Scholar
  • 32 Webster J, Piscitelli G, Polli A et al.. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.  N Engl J Med. 1994;  331(14) 904-909
    CrossrefPubMedGoogle Scholar
  • 33 Di Sarno A, Landi M L, Cappabianca P et al.. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.  J Clin Endocrinol Metab. 2001;  86(11) 5256-5261
    CrossrefPubMedGoogle Scholar
  • 34 Arafah B M, Nasrallah M P. Pituitary tumors: pathophysiology, clinical manifestations and management.  Endocr Relat Cancer. 2001;  8(4) 287-305
    CrossrefPubMedGoogle Scholar
  • 35 Arafah B M, Brodkey J S, Pearson O H. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies.  Metabolism. 1986;  35(10) 905-912
    CrossrefPubMedGoogle Scholar
  • 36 Molitch M E, Thorner M O, Wilson C. Management of prolactinomas.  J Clin Endocrinol Metab. 1997;  82(4) 996-1000
    CrossrefPubMedGoogle Scholar
  • 37 Schlechte J, Dolan K, Sherman B et al.. The natural history of untreated hyperprolactinemia: a prospective analysis.  J Clin Endocrinol Metab. 1989;  68(2) 412-418
    PubMedGoogle Scholar
  • 38 Jeffcoate W J, Pound N, Sturrock N D et al.. Long-term follow-up of patients with hyperprolactinaemia.  Clin Endocrinol (Oxf). 1996;  45(3) 299-303
    CrossrefPubMedGoogle Scholar
  • 39 Klibanski A, Neer R M, Beitins I Z et al.. Decreased bone density in hyperprolactinemic women.  N Engl J Med. 1980;  303(26) 1511-1514
    PubMedGoogle Scholar
  • 40 Biller B M, Baum H B, Rosenthal D I et al.. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.  J Clin Endocrinol Metab. 1992;  75(3) 692-697
    CrossrefPubMedGoogle Scholar
  • 41 Klibanski A, Biller B M, Rosenthal D I et al.. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.  J Clin Endocrinol Metab. 1988;  67(1) 124-130
    PubMedGoogle Scholar
  • 42 Molitch M E. Management of prolactinomas during pregnancy.  J Reprod Med. 1999;  44(12 suppl) 1121-1126
    PubMedGoogle Scholar
  • 43 Molitch M E. Pregnancy and the hyperprolactinemic woman.  N Engl J Med. 1985;  312(21) 1364-1370
    PubMedGoogle Scholar
  • 44 Kupersmith M J, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas.  Ann Intern Med. 1994;  121(7) 473-477
    PubMedGoogle Scholar
  • 45 Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.  Drug Saf. 1996;  14(4) 228-238
    PubMedGoogle Scholar
  • 46 Melmed S. Acromegaly.  Metabolism. 1996;  45(8 suppl 1) 51-52
    CrossrefPubMedGoogle Scholar
  • 47 Melmed S, Braunstein G D, Chang R J et al.. Pituitary tumors secreting growth hormone and prolactin.  Ann Intern Med. 1986;  105(2) 238-253
    PubMedGoogle Scholar
  • 48 Klibanski A, Zervas N T. Diagnosis and management of hormone-secreting pituitary adenomas.  N Engl J Med. 1991;  324(12) 822-831
    PubMedGoogle Scholar
  • 49 Fukuda I, Hizuka N, Murakami Y et al.. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University.  Intern Med. 2001;  40(10) 987-992
    PubMedGoogle Scholar
  • 50 Blumberg D L, Sklar C A, David R et al.. Acromegaly in an infant.  Pediatrics. 1989;  83(6) 998-1002
    PubMedGoogle Scholar
  • 51 Chandrashekar V, Bartke A. The role of insulin-like growth factor-I in neuroendocrine function and the consequent effects on sexual maturation: inferences from animal models.  Reprod Biol. 2003;  3(1) 7-28
    PubMedGoogle Scholar
  • 52 Lackey B R, Gray S L, Henricks D M. The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions.  Cytokine Growth Factor Rev. 1999;  10(3-4) 201-217
    CrossrefPubMedGoogle Scholar
  • 53 Barreca A, Artini P G, Del Monte P et al.. In vivo and in vitro effect of growth hormone on estradiol secretion by human granulosa cells.  J Clin Endocrinol Metab. 1993;  77(1) 61-67
    CrossrefPubMedGoogle Scholar
  • 54 Adashi E Y, Resnick C E, D'Ercole A J et al.. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function.  Endocr Rev. 1985;  6(3) 400-420
    PubMedGoogle Scholar
  • 55 Christman G M, Randolph Jr J F, Peegel H et al.. Differential responsiveness of luteinized human granulosa cells to gonadotropins and insulin-like growth factor I for induction of aromatase activity.  Fertil Steril. 1991;  55(6) 1099-1105
    PubMedGoogle Scholar
  • 56 Erickson G F, Garzo V G, Magoffin D A. Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells.  J Clin Endocrinol Metab. 1989;  69(4) 716-724
    PubMedGoogle Scholar
  • 57 Minegishi T, Hirakawa T, Abe K et al.. Effect of IGF-1 and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the expression of LH receptors during cell differentiation in cultured granulosa cells.  Mol Cell Endocrinol. 2003;  202(1-2) 123-131
    PubMedGoogle Scholar
  • 58 Kaltsas G A, Mukherjee J J, Jenkins P J et al.. Menstrual irregularity in women with acromegaly.  J Clin Endocrinol Metab. 1999;  84(8) 2731-2735
    CrossrefPubMedGoogle Scholar
  • 59 Luboshitzky R, Dickstein G, Barzilai D. Bromocriptine-induced pregnancy in an acromegalic patient.  JAMA. 1980;  244(6) 584-586
    CrossrefPubMedGoogle Scholar
  • 60 Lim N Y, Dingman J F. Androgenic adrenal hyperfunction in acromegaly.  N Engl J Med. 1964;  271 1189-1194
    PubMedGoogle Scholar
  • 61 Unal A, Sahin Y, Kelestimur F. Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report.  Endocr J. 1993;  40(2) 207-211
    PubMedGoogle Scholar
  • 62 Barkan A L, Beitins I Z, Kelch R P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.  J Clin Endocrinol Metab. 1988;  67(1) 69-73
    PubMedGoogle Scholar
  • 63 Arafah B M, Rosenzweig J L, Fenstermaker R et al.. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.  J Lab Clin Med. 1987;  109(3) 346-354
    PubMedGoogle Scholar
  • 64 Giustina A, Barkan A, Casanueva F F et al.. Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85(2) 526-529
    CrossrefPubMedGoogle Scholar
  • 65 Matsuno A, Ogino Y, Katayama H et al.. Identification of a silent pituitary somatotropic adenoma based on a paradoxic response of growth hormone on a thyrotropin-releasing hormone or gonadotropin-releasing hormone provocation test.  Am J Obstet Gynecol. 2001;  184(3) 286-288
    CrossrefPubMedGoogle Scholar
  • 66 Halse J, Harris A G, Kvistborg A et al.. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.  J Clin Endocrinol Metab. 1990;  70(5) 1254-1261
    PubMedGoogle Scholar
  • 67 Ayuk J, Stewart S E, Stewart P M et al.. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.  J Clin Endocrinol Metab. 2002;  87(9) 4142-4146
    CrossrefPubMedGoogle Scholar
  • 68 Colao A, Ferone D, Marzullo P et al.. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.  J Clin Endocrinol Metab. 2001;  86(6) 2779-2786
    CrossrefPubMedGoogle Scholar
  • 69 Schoof E, Dorr H G, Kiess W et al.. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy.  Horm Res. 2004;  61(4) 184-189
    PubMedGoogle Scholar
  • 70 Lado-Abeal J, Rodriguez-Arnao J, Newell-Price J D et al.. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.  J Clin Endocrinol Metab. 1998;  83(9) 3083-3088
    CrossrefPubMedGoogle Scholar
  • 71 Cunningham S K, McKenna T J. Dissociation of adrenal androgen and cortisol secretion in Cushing's syndrome.  Clin Endocrinol (Oxf). 1994;  41(6) 795-800
    CrossrefPubMedGoogle Scholar
  • 72 Ahima R S, Harlan R E. Glucocorticoid receptors in LHRH neurons.  Neuroendocrinology. 1992;  56(6) 845-850
    PubMedGoogle Scholar
  • 73 Chrousos G P, Schuermeyer T H, Doppman J et al.. NIH conference. Clinical applications of corticotropin-releasing factor.  Ann Intern Med. 1985;  102(3) 344-358
    PubMedGoogle Scholar
  • 74 Fukata J, Nakai Y, Imura H et al.. Human corticotropin-releasing hormone test in normal subjects and patients with hypothalamic, pituitary or adrenocortical disorders.  Endocrinol Jpn. 1988;  35(3) 491-502
    PubMedGoogle Scholar
  • 75 Kalgikar A M, Chandratreya S A, Goel A et al.. Inferior petrosal sinus sampling in the diagnostic evaluation of Cushing's syndrome: K.E.M. experience.  J Assoc Physicians India. 2005;  53 685-688
    PubMedGoogle Scholar
  • 76 Booth G L, Redelmeier D A, Grosman H et al.. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease.  J Clin Endocrinol Metab. 1998;  83(7) 2291-2295
    CrossrefPubMedGoogle Scholar
  • 77 Findling J W, Tyrrell J B. Occult ectopic secretion of corticotropin.  Arch Intern Med. 1986;  146(5) 929-933
    CrossrefPubMedGoogle Scholar
  • 78 Landolt A M, Valavanis A, Girard J et al.. Corticotrophin-releasing factor-test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease.  Clin Endocrinol (Oxf). 1986;  25(6) 687-696
    PubMedGoogle Scholar
  • 79 Tindall G T, Herring C J, Clark R V et al.. Cushing's disease: results of transsphenoidal microsurgery with emphasis on surgical failures.  J Neurosurg. 1990;  72(3) 363-369
    PubMedGoogle Scholar
  • 80 Mampalam T J, Tyrrell J B, Wilson C B. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases.  Ann Intern Med. 1988;  109(6) 487-493
    PubMedGoogle Scholar
  • 81 Semple P L, Vance M L, Findling J W et al.. Transsphenoidal surgery for Cushing's disease: outcome in patients with a normal magnetic resonance imaging scan.  Neurosurgery. 2000;  46(3) 553-558
    CrossrefPubMedGoogle Scholar
  • 82 Kurosaki M, Luedecke D K, Knappe U J et al.. The value of intraoperative cytology during transsphenoidal surgery for ACTH-secreting microadenoma.  Acta Neurochir (Wien). 2000;  142(8) 865-870
    CrossrefPubMedGoogle Scholar
  • 83 Esposito F, Dusick J R, Cohan P et al.. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease.  J Clin Endocrinol Metab. 2006;  91(1) 7-13
    CrossrefPubMedGoogle Scholar
  • 84 Nakane T, Kuwayama A, Watanabe M et al.. Long term results of transsphenoidal adenomectomy in patients with Cushing's disease.  Neurosurgery. 1987;  21(2) 218-222
    PubMedGoogle Scholar
  • 85 Shimon I, Ram Z, Cohen Z R et al.. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients.  Neurosurgery. 2002;  51(1) 57-61
    CrossrefPubMedGoogle Scholar
  • 86 Chaidarun S S, Klibanski A. Gonadotropinomas.  Semin Reprod Med. 2002;  20(4) 339-348
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Samuels M H, Ridgway E C. Glycoprotein-secreting pituitary adenomas.  Baillieres Clin Endocrinol Metab. 1995;  9(2) 337-358
    CrossrefPubMedGoogle Scholar
  • 88 Klibanski A. Nonsecreting pituitary tumors.  Endocrinol Metab Clin North Am. 1987;  16(3) 793-804
    PubMedGoogle Scholar
  • 89 Jameson J L, Klibanski A, Black P M et al.. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.  J Clin Invest. 1987;  80(5) 1472-1478
    PubMedGoogle Scholar
  • 90 Yamada S, Asa S L, Kovacs K et al.. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay.  J Clin Endocrinol Metab. 1989;  68(1) 73-80
    PubMedGoogle Scholar
  • 91 Hanson P L, Aylwin S J, Monson J P et al.. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas.  Eur J Endocrinol. 2005;  152(3) 363-370
    CrossrefPubMedGoogle Scholar
  • 92 Ghayuri M, Liu J H. Ovarian hyperstimulation syndrome caused by pituitary gonadotroph adenoma secreting follicle-stimulating hormone.  Obstet Gynecol. 2007;  109(2 pt2) 547-549
    PubMedGoogle Scholar
  • 93 Shimon I, Rubinek T, Bar-Hava I et al.. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma.  J Clin Endocrinol Metab. 2001;  86(8) 3635-3640
    CrossrefPubMedGoogle Scholar
  • 94 Kihara M, Sugita T, Nagai Y et al.. Ovarian hyperstimulation caused by gonadotroph cell adenoma: a case report and review of the literature.  Gynecol Endocrinol. 2006;  22(2) 110-113
    CrossrefPubMedGoogle Scholar
  • 95 Tashiro H, Katabuchi H, Ohtake H et al.. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl.  Fertil Steril. 1999;  72(1) 158-160
    CrossrefPubMedGoogle Scholar
  • 96 Roberts J E, Spandorfer S, Fasouliotis S J et al.. Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma.  Fertil Steril. 2005;  83(1) 208-210
    CrossrefPubMedGoogle Scholar
  • 97 Ambrosi B, Bassetti M, Ferrario R et al.. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies.  Acta Endocrinol (Copenh). 1990;  122(5) 569-576
    PubMedGoogle Scholar
  • 98 Faggiano M, Criscuolo T, Perrone L et al.. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma.  Acta Endocrinol (Copenh). 1983;  102(2) 167-172
    PubMedGoogle Scholar
  • 99 Cook D M, Watkins S, Snyder P J. Gonadotrophin-secreting pituitary adenomas masquerading as primary ovarian failure.  Clin Endocrinol (Oxf). 1986;  25(6) 729-738
    PubMedGoogle Scholar
  • 100 Somjen D, Tordjman K, Kohen F et al.. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas.  Clin Endocrinol (Oxf). 1997;  46(5) 555-562
    CrossrefPubMedGoogle Scholar
  • 101 Lamberts S W, Verleun T, Oosterom R et al.. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro.  J Clin Endocrinol Metab. 1987;  64(3) 524-530
    PubMedGoogle Scholar
  • 102 White M C, Daniels M, Newland P et al.. LH and FSH secretion and responses to GnRH and TRH in patients with clinically functionless pituitary adenomas.  Clin Endocrinol (Oxf). 1990;  32(6) 681-688
    PubMedGoogle Scholar
  • 103 Chanson P, Schaison G. Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma.  J Clin Endocrinol Metab. 1995;  80(7) 2267-2268
    CrossrefPubMedGoogle Scholar
  • 104 Frankart L, De Hertogh R, Donckier J et al.. Pituitary apoplexy of a gonadotrophinoma and TRH/GnRH tests. Literature review.  Acta Clin Belg. 1995;  50(3) 163-170
    PubMedGoogle Scholar
  • 105 Shomali M E, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.  Pituitary. 2002;  5(2) 89-98
    CrossrefPubMedGoogle Scholar
  • 106 Sassolas G, Lejeune H, Trouillas J et al.. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.  J Clin Endocrinol Metab. 1988;  67(1) 180-185
    PubMedGoogle Scholar
  • 107 McGrath G A, Goncalves R J, Udupa J K et al.. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist.  J Clin Endocrinol Metab. 1993;  76(5) 1363-1368
    CrossrefPubMedGoogle Scholar
  • 108 Beck-Peccoz P, Brucker-Davis F, Persani L et al.. Thyrotropin-secreting pituitary tumors.  Endocr Rev. 1996;  17(6) 610-638
    CrossrefPubMedGoogle Scholar
  • 109 Southren A L, Olivo J, Gordon G G et al.. The conversion of androgens to estrogens in hyperthyroidism.  J Clin Endocrinol Metab. 1974;  38(2) 207-214
    PubMedGoogle Scholar
  • 110 Akande E O, Hockaday T D. Plasma concentration of gonadotrophins, oestrogens and progesterone in thyrotoxic women.  Br J Obstet Gynaecol. 1975;  82(7) 541-551
    PubMedGoogle Scholar
  • 111 Kalro B N. Impaired fertility caused by endocrine dysfunction in women.  Endocrinol Metab Clin North Am. 2003;  32(3) 573-592
    CrossrefPubMedGoogle Scholar
  • 112 Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas.  Pituitary. 2002;  5(2) 83-88
    CrossrefPubMedGoogle Scholar
  • 113 Kourides I A, Ridgway E C, Weintraub B D et al.. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors.  J Clin Endocrinol Metab. 1977;  45(3) 534-543
    PubMedGoogle Scholar
  • 114 Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary-adenomas.  Trends Endocrinol Metab. 1992;  3(2) 41-45
    PubMedGoogle Scholar
  • 115 Bertherat J, Brue T, Enjalbert A et al.. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.  J Clin Endocrinol Metab. 1992;  75(2) 540-546
    CrossrefPubMedGoogle Scholar
  • 116 Kuhn J M, Arlot S, Lefebvre H et al.. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.  J Clin Endocrinol Metab. 2000;  85(4) 1487-1491
    CrossrefPubMedGoogle Scholar
  • 117 Caron P, Arlot S, Bauters C et al.. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.  J Clin Endocrinol Metab. 2001;  86(6) 2849-2853
    CrossrefPubMedGoogle Scholar
  • 118 Fischler M P, Reinhart W H. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide.  J Endocrinol Invest. 1999;  22(1) 64-65
    PubMedGoogle Scholar
  • 119 Faglia G, Beck-Peccoz P, Piscitelli G et al.. Inappropriate secretion of thyrotropin by the pituitary.  Horm Res. 1987;  26(1-4) 79-99
    PubMedGoogle Scholar
  • 120 Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment.  Ann Intern Med. 1982;  96(3) 281-286
    PubMedGoogle Scholar

Lisa M HalvorsonM.D. 

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Medical Center at Dallas

5323 Harry Hines Blvd., J6-114, Dallas, TX 75390

Email: Lisa.Halvorson@UTSouthwestern.edu